With the successful conclusion of the 2025 European Biotech Conference & Exhibition (BIO-Europe 2025) in Vienna, Austria, MingCeler Biotech's participation in this premier biopharmaceutical industry event has drawn to a perfect close.
 

BIO-Europe 2025, co-organized by EBD Group and BIO, stands as one of Europe's largest and most influential biopharmaceutical industry gatherings. The conference brought together leading experts, entrepreneurs, and investors from the global biotechnology sector to discuss the latest research achievements, development trends, and future prospects in biopharmaceuticals, injecting new vitality into the industry's innovative development.
 

 

Image source: CBPF Biopharmaceutical Industry Conference.

 

During the event, MingCeler Biotech, as an animal model technology R&D company specializing in rapid, personalized customization services for various genetically modified mouse models, actively engaged with the global biopharmaceutical community.
 

 

Professor Wu Guangming, Chairman of MingCeler Biotech, and the Deputy Director of International Business Marketing attended the exhibition.

 

At the booth, MingCeler Biotech showcased its TurboMice™ tetraploid complementation technology and gene-edited mouse model construction services. The exhibition attracted numerous visitors who showed keen interest in the technology. The Deputy Director of International Business Marketing actively introduced products and technologies to clients, engaging in professional exchanges and industry demand discussions with peers, addressing client inquiries, and coordinating with their follow-up requirements.
 

 

MingCeler Biotech's TurboMice™ tetraploid complementation technology bypasses the time-consuming breeding and screening steps of conventional methods, significantly shortening the model construction cycle. This globally leading technology can greatly accelerate vaccine development, new drug R&D, precision medicine, and emergency public health research projects. It also provides the possibility for rapid preparation of complex animal models required in disease research, potentially significantly advancing related research in the life sciences field.
 

The company's participation not only demonstrated its technical capabilities but also strengthened connections with the global biopharmaceutical community. BIO-Europe 2025 provided MingCeler Biotech with a valuable platform to showcase its strengths and explore collaboration opportunities. We look forward to translating the insights and connections from the conference into tangible collaborative outcomes and continuing to drive the advancement of biotechnology. Let's look forward to our next gathering!
 

With continuous excitement and unwavering progress, MingCeler Biotech will remain dedicated to the innovative R&D of next-generation model animal preparation technology—TurboMice™ tetraploid complementation technology—providing superior mouse models and customized services to empower the rapid development of the biopharmaceutical industry with innovative technology.